Industry2h ago
Industry
Insilico Medicine Names New Preclinical Drug Candidate
Insilico Medicine nominated ISM9077 as a preclinical candidate for treating ocular diseases and inflammatory disorders. The company used its Chemistry42 platform to design and optimize the target Y inhibitor. This incremental step validates their AI-driven drug discovery pipeline. Practitioners should monitor whether this specific molecule reaches human clinical trials.